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Introduction
Sexual maturation and reproduction are regulated by the hypo-
thalamus, pituitary, and gonads. These endocrine organs form an 
integrated system known as the hypothalamic-pituitary-gonadal 
(HPG) axis, which is responsible for the adequate secretion of male 
and female sex hormones (1). The endocrine components of the 
reproductive system are hierarchically organized and integrated in 
a classical endocrine feedback loop. The HPG axis is active during 
development and shortly after birth, silenced during childhood 
by inhibitory neurotransmitters, and reawakened at the onset of 
puberty by pulsatile secretion of gonadotropin-releasing hormone 
(GnRH), a decapeptide that is synthesized by neurons located in the 
mediobasal hypothalamus (2, 3). During development, GnRH neu-
rons originate from the olfactory placode of the olfactory system and 
migrate to the hypothalamus, where they control reproduction by 
secreting GnRH into a capillary network that transmits GnRH to the 
anterior pituitary to stimulate secretion of follicle-stimulating hor-
mone (FSH, encoded by Fshb) and luteinizing hormone (LH, encod-
ed by Lhb). Secreted GnRH acts via the GnRH receptor, which is 
expressed on gonadotropic cells in the anterior pituitary gland. This 
action regulates synthesis and release of both gonadotropins, LH 
and FSH, that control gonadal maturation and adult reproductive 
physiology via stimulation of sex steroid synthesis (1). In males, FSH 
stimulates proliferation of immature Sertoli cells and spermatogo-
nia, whereas LH stimulates Leydig cells to produce testosterone 
(4). In females, LH triggers ovulation, promotes development of the 
corpus luteum, and stimulates theca cells to produce androgens, 
whereas FSH stimulates recruitment of secondary ovarian follicles 
and the secretion of estradiol from granulosa cells, thereby promot-
ing follicular maturation, which ultimately leads to ovulation (5).
Lack of activation of the HPG axis leads to hypogonado-
tropic hypogonadism, which is defined as low levels of the sex 
steroids testosterone or estrogen (hypogonadism) in male or 
female patients, respectively, and inappropriately low levels of 
gonadotropins FSH and LH (6). An increasing number of genes 
have been implicated in the molecular pathogenesis of congen-
ital isolated hypogonadotropic hypogonadism (IHH), under-
lining the genetic and clinical heterogeneity and complexity of 
this condition (7–9). Genetic causes of GnRH and gonadotropin 
deficiency can be grouped according to the nature of their patho-
genic mechanisms, which comprise defects in neuropeptides and 
proteins involved in the development and migration of GnRH 
neurons (caused by mutations in KAL1, FGF8/FGFR1, PROK2/ 
PROKR2, CHD7, HS6ST1, WDR11, FEZF1, NSMF and SEMA3A) 
in genes controlling GnRH secretion and action (GNRH1, GPR54 
[also known as KISS1], TAC3/TACR3, LEP/LEPR, and GNRHR, 
respectively) and genes participating in synthesis of LH or FSH β 
subunits (7–9). Interestingly, homozygous inactivating mutations 
in the genes encoding the ubiquitin E3 ligase RNF216 and the 
deubiquitinase OTUD4 have recently been identified by whole- 
exome sequencing in patients exhibiting a syndrome of hypogo-
nadotropic hypogonadism, progressive ataxia, and dementia, 
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MicroRNAs (miRNAs) are small noncoding RNAs that act 
as negative regulators of gene expression by binding to miRNA- 
response elements (MREs) located primarily in 3′ UTRs of mRNA 
targets to regulate their stability and translation (12). Mammalian 
genomes have more than 500 miRNA genes, with miRNAs from 
individual gene families often targeting hundreds of different 
thereby linking disordered ubiquitination to neurodegeneration 
and reproductive dysfunction (10). Despite these recent advanc-
es, the genetic basis of many cases of congenital IHH remains 
unknown, as these mutations account for approximately 50% of 
all IHH cases (11). Therefore, discovering additional gene muta-
tions will continue to advance our understanding of this syndrome.
Figure 1. Ablation of mir-7a2 leads to male hypogonadism. (A–C) Representative images of mir-7a2 WT (+/+) control and KO (–/–) testes (A) and quantifica-
tion of testes weights (B) of mir-7a1 KO, mir-7a2 KO, or respective WT controls (mir-7a1 control, n = 7; mir-7a1 KO, n = 6; mir-7a2 control, n = 14; mir-7a2 KO,  
n = 9) at 6 to 8 weeks of age or (C) at 14 days (mir-7a2 control, n = 4; mir-7a2 KO, n = 2). Scale bar: 5 mm. (D and E) Immunohistological images (D) and quanti-
fication (E) of CYP17A1-positive Leydig cells (WT, mir-7a2 KO, n = 3). Scale bars: 50 μm. Arrows show Leydig cells. (F) Relative expression levels of steroidogenic 
genes in testes of mir-7a2 KO or control mice (WT, n = 9; mir-7a2 KO, n = 7). (G and H) Representative images of seminal vesicles (G) and quantification of 
weights (H) of control (upper) or mir-7a2 KO (lower) mice (WT, n = 6; mir-7a2 KO, n = 4). Scale bar: 5 mm. (I) Intratesticular testosterone levels normalized per 
total protein content in mir-7a2 KO or control mice (WT, n = 5; mir-7a2 KO, n = 3). (J) Total sperm count of the cauda epididymidis of 12-week-old mir-7a2 KO or 
control mice (WT, n = 5; mir-7a2 KO, n = 3). All data are represented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001, ANOVA (B); t test (C, E, F, H, I, J).
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approximately 50% reduced testes weights at pre- and pubertal 
ages (2 and 6 to 8 weeks old, respectively) (Figure 1, A–C). The 
body weights and lengths of mir-7a2 KO mice were comparable 
with those of WT or mir-7a1 KO animals (Supplemental Figure 1, E 
and F). Histological analysis of mir-7a2 KO testes revealed smaller 
but developed seminiferous tubules, with diminished numbers of 
spermatocytes, spermatids, and spermatozoa (Supplemental Fig-
ure 1G). Immunohistochemical quantification of the Leydig cell 
marker CYP17A1 showed that testosterone-producing Leydig cells 
were reduced by more than 50% in mir-7a2 KO mice (Figure 1, D 
and E). We analyzed expression levels of steroidogenic enzymes in 
testes and measured an approximately 50% reduction of Cyp17a1 
and Hsd3b6 mRNAs, which are required for dehydroepiandroste-
rone and testosterone synthesis, respectively (Figure 1F). Interest-
ingly, expression levels of the FSH receptor (Fshr) and LH receptor 
(Lhcgr) were increased by 2-fold, most likely due to a compensa-
tory response to the decreased plasma gonadotrophin levels (29). 
The sizes and weights of seminal vesicles, a classic target organ 
of testosterone, were reduced by 75% (Figure 1, G and H). Con-
comitantly, levels of intratesticular testosterone were decreased in 
mir-7a2 KO mice (Figure 1I) and the total sperm count of the cau-
da epididymidis, where mature sperm is stored, revealed a 75% 
decrease in mir-7a2 KO mice as compared with WT controls (Fig-
ure 1J). Finally, the inguinal fat pad weights were increased 260% 
in 16-week-old mice (Supplemental Figure 1H).
Analogous to the phenotype observed in males, mir-7a2 KO 
females had normal body weight and length (Supplemental Fig-
ure 1, I and J), but exhibited a reduced size of estrogen hormone 
target organs, as evidenced by reduced ovary weights and thread-
like atrophied uteri compared with WT or mir-7a1 KO mice (Fig-
ure 2, A and B). Histological analysis revealed that ovaries of mir-
7a2 KO mice were able to form secondary and tertiary follicles 
that were comparable to those of WT mice; however, they lacked 
late-stage antral follicles or corpora lutea, consistent with failure 
of folliculogenesis and ovulation (Figure 2, C and D). Expression 
analysis of steroidogenic genes in mir-7a2 KO ovaries revealed a 
drastic decrease of Cyp19a1 mRNA, also known as aromatase, the 
key enzyme in estradiol biosynthesis (Figure 2E). Consequently, 
plasma levels of estradiol were reduced by 35% in mir-7a2 KO 
female mice (Figure 2F). Furthermore, as in male mice, gonadal 
fat pad weights were increased and dual energy x-ray absorptiom-
etry (DEXA) measurements of fat and lean body mass revealed 
increased fat and decreased lean mass in 16-week-old mir-7a2 KO 
mice compared with WT littermate mice (Supplemental Figure 1, 
K–M), consistent with the hypogonadal-induced obesity observed 
in mice and humans (30, 31). Together, these data illustrate that 
loss of mir-7a2, but not mir-7a1 or mir-7b, is sufficient to induce 
hypogonadism and infertility in mice.
miR-7a2 is the predominant miR-7 family member and is enriched 
in the pituitary. Based on the increased testicular expression of 
Fshr and Lhcgr, which suggests decreased plasma levels of the 
pituitary hormones FSH and LH, we hypothesized that the gonad-
al dysfunction and infertility observed in male and female mir-
7a2 KO mice resulted from impaired pituitary function. First, we 
systematically analyzed expression levels of miR-7a and miR-
7b by absolute quantification in tissues of the hypothalamic- 
pituitary-adrenal/gonadal axis. We found that miR-7a and miR-7b 
mRNAs (13, 14). With more than half of all human mRNAs esti-
mated to be conserved miRNA targets, miRNAs are thought to 
have widespread effects on gene regulation. Many miRNA knock-
out models in mice show no apparent defect under normal condi-
tions; however, they frequently exhibit severe miRNA-dependent 
phenotypes when specific stresses are applied (15). Moreover, the 
importance of individual miRNAs in normal physiology and dis-
ease has been established by the discovery of mutations in miRNAs 
and their targets (16–18). Recently, the collective role of miRNAs 
in the HPG axis was demonstrated by genetic ablation of Dicer1 in 
GnRH neurons (19) and gonadotrophs (20), resulting in hypogo-
nadism and infertility. Furthermore, miR-200b and miR-429, both 
members of the miR-200 family, as well as their target, ZEB1, are 
required for female ovulation and reproduction in mice (21).
The miR-7 family is evolutionarily highly conserved and con-
sidered a prototypical neuroendocrine miRNA, being expressed 
at high levels in neurons and neuroendocrine organs, most nota-
bly the endocrine pancreas, pituitary, and adrenal glands (14, 22, 
23). Mature miR-7 harbors a conserved seed sequence that is pro-
cessed from 3 precursors – miR-7a1, miR-7a2, and miR-7b – that 
are transcribed from unlinked loci on murine chromosomes 13, 7, 
and 17, respectively. A novel mechanism of miR-7 regulation was 
recently described in neuronal cells through the identification of 
a brain-enriched circular RNA (known as antisense to the cerebel-
lar degeneration–related protein 1 transcript [Cdr1as]) comprising 
several dozens of conserved miR-7–binding sites counteracting 
repression by this miRNA (24, 25). Functionally, miR-7 has been 
implicated in organ differentiation and development (26) as well 
as in mammalian neurodegenerative diseases and cancer (27, 28). 
Mouse genetic studies so far have revealed a role in insulin secre-
tion and differentiation of pancreatic β cells (22).
In this study, we describe the unexpected finding of a hypogo-
nadotropic hypogonadism phenotype in male and female mice as a 
result of the single mir-7a2 deletion. We identify miR-7a2 as a positive 
regulator of FSH and LH synthesis by controlling a network involv-
ing bone morphogenetic protein 4 (BMP4) and prostaglandin signal-
ing. Our data reveal the indispensability of a single miRNA for nor-
mal pituitary gonadotroph function, raising the question of whether 
genetic or acquired defects leading to altered miR-7 levels may be 
responsible for puberty and infertility disorders of pituitary origin.
Results
Genetic ablation of mir-7a2, but not mir-7a1 or mir-7b, leads to hypo-
gonadism and infertility in mice. To investigate the physiological 
role of miR-7, we generated mice constitutively lacking mir-7a1 
(referred to as mir-7a1 KO), mir-7a2 (referred to as mir-7a2 KO), 
or mir-7b (referred to as mir-7b KO) (Supplemental Figure 1, A–D; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI90031DS1). Heterozygous breedings of all 3 
mouse strains were viable, had unaltered body weight and body 
length, and were born at normal Mendelian ratios (Supplemental 
Figure 1, E–H). Interestingly, homozygous mir-7a2 KO male and 
female mice were infertile, while homozygous mir-7a1 KO or mir-
7b KO mice remained fertile, with unaltered reproductive rates 
(Supplemental Table 1).
Homozygous mir-7a2 KO male mice failed to undergo sexual 
maturation and exhibited microphallus and hypogonadism with 
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were enriched in pituitary as compared with hypothalamus (10-
fold less), adrenal gland (50-fold less), or gonads (up to 500-fold 
less) and that miR-7a was 2.5-fold more abundant than miR-7b in 
pituitary (Supplemental Figure 2, A and B). Given the low expres-
sion of miR-7a in male and female gonads, it is unlikely that miR-
7a would repress target genes and exert a biological function in 
testis and ovary (32).
As pre-miR-7a1 and pre-miR-7a2 are processed into an iden-
tical mature miR-7a sequence, the TaqMan probe of the miRNA 
assay cannot distinguish between the 2 miRNA gene products 
and thus measures combined miR-7a1 and miR-7a2 levels. To 
assess the contribution of miR-7a1 and miR-7a2 to the total pool 
of miR-7a in the pituitary, we analyzed expression levels of miR-
7a in mice lacking either mir-7a1 or mir-7a2. Interestingly, total 
miR-7a expression was reduced by approximately 80% in mir-7a2– 
deficient mice, while miR-7a levels appeared to be unchanged in 
mice lacking mir-7a1 when compared with WT littermate animals 
(Supplemental Figure 2, C–F). Expression of miR-7b was unchanged 
in mir-7a1– and mir-7a2–deficient mice compared with WT animals, 
thereby confirming the specificity of the TaqMan assay.
In conclusion, miR-7a2 is highly enriched in pituitary com-
pared with other neuroendocrine tissues; furthermore, it accounts 
for the large majority of total pituitary miR-7 copies, and miR-7a1 
and miR-7b cannot compensate for loss of miR-7a2 expression.
miR-7a2 ablation causes hypopituitarism and hypogonadotrop-
ic hypogonadism. To test whether the hypogonadism observed 
in mir-7a2 KO mice was caused by altered gene expression of 
essential pituitary genes, we performed RNA sequencing (RNA-
Seq) of pituitaries from 6-week-old WT and mir-7a2 KO mice. We 
measured a dramatic decrease of gonadotropin expression with 
a reduction of Fshb mRNA by 86% (FDR = 5.94 × 10-52) and Lhb 
mRNA by 78% (FDR = 1.26 × 10-82) in mir-7a2–deficient pituitaries 
that was already apparent in 2-week-old mice (Figure 3A and Sup-
plemental Figure 3A). In addition, expression of the glycoprotein 
hormone α subunit (Cga) and prolactin (Prl) mRNAs was reduced, 
while the expression of the GnRH receptor (Gnrhr) and other hor-
mones of the anterior pituitary, including thyroid stimulating hor-
mone β (Tshb), growth hormone (Gh), and pro-opiomelanocortin 
-α (Pomc), remained unchanged. Since lack of Prl does not lead to 
hypogonadism (33), we focused our investigation on the charac-
terization of gonadotroph cells. Immunohistochemical analysis of 
pituitary sections revealed reduced numbers of FSH-expressing 
(–66%) and LH-expressing (–60%) cells in mir-7a2 KO mice (Fig-
ure 3, B–E). We also observed that pituitary weights were reduced 
Figure 2. Ablation of mir-7a2 leads to female hypogonadism and anovu-
lation. (A and B) Representative images of ovaries and uteri (A) and quan-
tification of ovary weights (B) of mir-7a1 KO, mir-7a2 KO, or respective 
control mice (mir-7a1 control, n = 9; mir-7a1 KO, n = 10; mir-7a2 control,  
n = 7; mir-7a2 KO, n = 4). Scale bar: 5 mm. (C and D) Histological exam-
ination using H&E staining of ovaries of WT control (C) or mir-7a2 KO 
(D) mice (n = 4). CL, corpus luteum; LAF, large antral follicle; GF, growing 
follicle. Shown are representative images of 4 mice per genotype. Scale 
bar: 100 μm. (E) Relative expression levels of ovarian steroidogenic genes 
in mir-7a2 KO or control mice (WT, n = 6; mir-7a2 KO, n = 4). (F) Plasma 
estradiol levels of 8-week-old mir-7a2 KO or control mice (WT, n = 12;  
mir-7a2 KO, n = 11). All data are represented as mean ± SD. *P < 0.05;  
**P < 0.01; ***P < 0.001, ANOVA (B); t test (E, F).
Downloaded from http://www.jci.org on February 22, 2017.   https://doi.org/10.1172/JCI90031
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5jci.org
impaired and that the defect in mir-7a2 KO mice is primarily at the 
level of the pituitary (Supplemental Figure 3, B and C). We then 
tested whether the hypopituitarism observed in mir-7a2 KO mice 
was responsible for the impaired gonadal function and anovu-
lation by subjecting female mice to a standard superovulation 
treatment using pregnant mare serum. Ovulation was induced in 
hormone-treated mir-7a2 KO mice, indicating that ovaries were 
in both male and female mir-7a2 KO mice (Figure 3, F and G). 
Importantly, the observed alterations of gene expression resulted 
in strongly decreased plasma concentrations of FSH and LH in 
male and female mir-7a2 KO mice (Figure 3, H–K). Furthermore, 
a GnRH stimulation test with buserelin revealed an increase of 
plasma FSH and LH levels in WT, but not mir-7a2 KO mice, fur-
ther confirming that the response of gonadotropic cells to GnRH is 
Figure 3. Constitutive genetic ablation of mir-7a2 causes hypogonadotropic hypogonadism. (A) Expression of pituitary hormones in male mir-7a2 KO or 
control mice shown as heat map analysis from RNA-Seq (WT, mir-7a2 KO, n = 3). (B and C) Representative immunohistological images of pituitary sections 
(n = 3) stained for LH (B) or FSH (C) of control (upper images) or mir-7a2 KO mice (lower images). Scale bars: 200 μm. (D and E) Quantification of LH-positive 
(D) or FSH-positive (E) cells in pituitary of mir-7a2 KO or control mice (WT, mir-7a2 KO, n = 3). (F and G) Pituitary weights of male (F) or female (G) mir-7a1 KO, 
mir-7a2 KO, or respective control mice (males, mir-7a1 control, mir-7a1 KO, n = 4; mir-7a2 control, mir-7a2 KO, n = 8; mir-7a1 control, n = 8; mir-7a1 KO,  
n = 10; mir-7a2 control, n = 6; mir-7a2 KO, n = 7). (H and I) Plasma levels of FSH (H) or LH (I) in male mir-7a2 KO or control mice (WT, mir-7a2 KO, n = 7). (J and 
K) Plasma levels of FSH (J) or LH (K) in female mir-7a2 KO or control mice (WT, mir-7a2 KO, n = 4). (L) Number of oocytes collected after superovulation test 
in 5-week-old mir-7a2 KO or control mice (WT, n = 4; mir-7a2 KO, n = 3). All data are represented as mean ± SD except in (H, K), where data are represented as 
± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, ANOVA (F, G); t test (D, E, H, I, J, K).
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principally functional and that hypophyseal-pituitary dysfunction 
was the primary cause for the hypogonadism in mir-7a2–ablated 
mice (Figure 3L). We can exclude that the relatively low expres-
sion of miR-7a in the hypothalamus affects GnRH-expressing 
neurons, as Gnrh mRNA levels, morphology, and expected pro-
jections of GnRH-expressing neurons were unaltered in mir-7a2 
KO mice (Supplemental Figure 3, D–F). Furthermore, transcript 
levels of neuropeptides and genes involved in the development 
and migration of GnRH neurons and expression of genes con-
trolling GnRH secretion and action were similar in hypothalami 
of mir-7a2 KO and control littermates (Supplemental Figure 3, G 
and H). Interestingly, the neuropeptides kisspeptin 1 (Kiss1) and 
tachykinin 2 (Tac2) were significantly increased in hypothalami 
of mir-7a2 KO mice, which corroborates findings that Kiss1 and 
Tac2 expression are under inhibitory modulation from circulating 
gonadal hormones (34, 35). In addition, olfactory bulbs appeared 
to have normal size and architecture and no difference was detect-
ed in behavioral olfactory testing of male and female mice lacking 
Figure 4. Acute ablation of mir-7a2 in adult mice recapitulates hypogonadotropic hypogonadism. (A) TaqMan assays showing relative expression levels 
of miR-7a2, miR-7b, or miR-16 in pituitary of male UBC-Cre × mir-7a2fl/fl or Cre-negative mir-7a2fl/fl mice 10 weeks after a 5-day treatment with tamoxifen 
(TAM) or vehicle (UBC-Cre × mir-7a2fl/fl + vehicle, n = 5, mir-7a2fl/fl + TAM, UBC-Cre × mir-7a2fl/fl + TAM, n = 4). (B) Relative expression levels of pituitary hor-
mones in UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl mice after treatment with tamoxifen or vehicle (UBC-Cre × mir-7a2fl/fl + vehicle, n = 5, mir-7a2fl/fl + TAM,  
UBC-Cre × mir-7a2flox + TAM, n = 4). (C and D) Immunohistological quantification of LH-positive (C) or FSH-positive (D) cells in pituitary sections of  
UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl mice after treatment with tamoxifen (mir-7a2fl/fl + TAM, n = 4; UBC-Cre × mir-7a2fl/fl + TAM, n = 3). (E and F) Plasma levels 
of FSH (E) or LH (F) of male UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl mice after treatment with tamoxifen or vehicle (FSH, UBC-Cre × mir-7a2fl/fl + vehicle, n = 5; 
mir-7a2fl/fl + TAM, UBC-Cre × mir-7a2fl/fl + TAM, n = 4; LH, UBC-Cre × mir-7a2fl/fl + vehicle, mir-7a2fl/fl + TAM, UBC-Cre × mir-7a2fl/fl + TAM, n = 3). (G) Testes 
weights of UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl mice after treatment with tamoxifen or vehicle (UBC-Cre × mir-7a2fl/fl + vehicle, n = 6; mir-7a2fl/fl + TAM,  
n = 10; UBC-Cre × mir-7a2fl/fl + TAM, n = 8). (H) Relative expression levels of the Leydig cell marker CYP17A1 in testes of UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl  
mice after treatment with tamoxifen or vehicle (UBC-Cre × mir-7a2fl/fl + vehicle, mir-7a2fl/fl + TAM, UBC-Cre × mir-7a2fl/fl + TAM, n = 4). All data are repre-
sented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001, ANOVA (A, B, E, F, G, H); t test (C and D).
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mir-7a2 compared with littermate controls (data not shown, Sup-
plemental Figure 3I), suggesting that the hypogonadotropic phe-
notype was not due to defective GnRH neuron migration from the 
olfactory placode into the correct hypothalamic location during 
development. Collectively, these data demonstrate that mir-7a2 
deficiency causes pituitary dysfunction and mirrors the disease 
pathology of human hypogonadotropic hypogonadism.
Acute genetic ablation of miR-7a2 in adult mice recapitulates 
hypogonadotropic hypogonadism. To circumvent potential devel-
opmental effects caused by constitutive mir-7a2 ablation, we 
bred mice carrying a floxed mir-7a2 allele (referred to as mir-
7a2fl/fl) with transgenic mice expressing Cre-recombinase fused 
to a mutant form of the estrogen receptor ERT2 under the tran-
scriptional control of the human ubiquitin C promoter (UBC-
Figure 5. Pituitary gene expression analysis and identification of target genes of mir-7a2. (A) Expression of key pituitary markers in mir-7a2 KO or control 
mice shown as heat map analysis from RNA-Seq of 6-week-old male mice (WT, mir-7a2 KO, n = 3). (B) Relative expression of key pituitary markers in UBC-
Cre × mir-7a2fl/fl or Cre-negative mir-7a2fl/fl mice 10 weeks after a 5-day treatment with tamoxifen or vehicle (UBC-Cre × mir-7a2fl/fl + vehicle, n = 5, mir-7a2fl/fl 
+ TAM, UBC-Cre × mir-7a2fl/fl +TAM, n = 4). (C) RNA-Seq results from pituitary of 6-week-old male mir-7a2 KO or control mice. Cumulative distributions 
of mRNA changes for predicted target genes of miR-7 (left)or miR-16 (right) with the indicated context+ score bins (color) or for genes with no respective 
miRNA site (black), as scored by the context+ model of TargetScan 6.2 (60). Number of genes per bin for miR-7: black, 11,884; green, 1,927; orange, 782; red, 
245; purple, 83; miR-16: black, 12,841; green, 656; orange, 967; red, 306; purple, 151. (WT, mir-7a2 KO, n = 3). (D) Relative expression of predicted miR-7 tar-
get genes that were more than 1.3-fold upregulated in RNA-Seq in pituitaries of UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl mice 10 weeks after a 5-day treatment 
with tamoxifen relative to vehicle-treated mice (set as 1, black dotted line) (mir-7a2fl/fl + TAM, n = 4; UBC-Cre × mir-7a2fl/fl + TAM, n = 3). (E) Relative mRNA 
expression levels of miR-7 targets Glg1 and Ptgfrn in pituitary of WT control (mir-7a2+/+) or mir-7a2 KO (mir-7a2–/–) mice (n = 4). All data are represented as 
mean ± SD. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001, ANOVA (B and C); t test (A, D, E).
Downloaded from http://www.jci.org on February 22, 2017.   https://doi.org/10.1172/JCI90031
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
8 jci.org
that received only vehicle (Figure 4B). Immunohistochemical 
quantification revealed that FSH cell area was reduced by 55% in 
tamoxifen-treated UBC-Cre × mir-7a2fl/fl mice, while LH cell area 
decreased to a lesser extent, with borderline significance (Figure 
4, C and D). Most notably, acute ablation of mir-7a2 in adult mice 
led to a drastic reduction of plasma FSH and LH levels (Figure 4, E 
and F), and importantly, these hormones were unaltered between 
vehicle-treated UBC-Cre × mir-7a2fl/fl and mir-7a2fl/f mice that 
received tamoxifen (Figure 4, E and F). The decreased gonadotro-
pin expression and secretion resulted in reduced testes weights in 
Cre) (36) to allow tamoxifen-inducible global ablation of mir-7a2 
(referred to as UBC-Cre × mir-7a2fl/fl). We treated 6-week-old 
male UBC-Cre × mir-7a2fl/fl or mir-7a2fl/fl mice with tamoxifen or 
vehicle and confirmed ablation of mir-7a2 using a TaqMan miR-
NA assay 8 weeks after treatment (Figure 4A). While pituitary 
weight and body weight remained unchanged between groups 
(Supplemental Figure 3, J and K), a striking 50% reduction of 
Fshb and Lhb mRNA expression levels was observed in the pitu-
itaries of tamoxifen-treated UBC-Cre × mir-7a2fl/fl mice as com-
pared with control mir-7a2fl/fl mice or UBC-Cre × mir-7a2fl/fl mice 
Figure 6. miR-7a2 regulates gonadotropin production through BMP and prostaglandin signaling. (A and B) Relative luciferase levels of plasmids car-
rying WT or mutated 3′ UTRs of Ptgfrn (A) or Glg1 (B) cotransfected in LbT2 cells with or without forced expression of mir-7a2 (n = 3). (C and D) Relative 
expression levels of gonadotropin genes in cells transfected with siRNA against Ptgfrn (C) or Glg1 (D) (n = 4). (E) Relative expression levels of gonadotropin 
genes, Cga, Fshb, and Lhb in cells overexpressing Ptgfrn (gray bars) or Glg1 (black bars) for 72 hours (n = 4). (F and G) Relative expression levels of Fshb (F) 
or Lhb (G) in LbT2 cells that were transfected with siPtgfrn or siCtrl and treated with 100 nM dinoprost or PBS for 4 hours (n = 4). (H) Concentration of LH 
in supernatants of cells 72 hours after silencing of Ptgfrn (n = 3). (I) Expression levels of Lhb in cells treated with dinoprost (100 nM), GREM1 (0.25 μg/ml), 
or dinoprost and GREM1 together (n = 3). (J) Western blot analysis of phospho-SMAD1/5/9 or total SMAD1 in lysates of cells pretreated with or without 
GREM1 (0.25 ug/ml) for 1 hour, followed by 30 minutes of stimulation with BMP4 (50 ng/ml). Shown is 1 representative experiment of 3. All data are repre-
sented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001, ANOVA (E, F, G, I); t test (A, B, C, D, H).
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further validated by quantitative PCR (qPCR) that the mRNA tran-
scripts of Ptgfrn and golgi glycoprotein 1 (Glg1), a member of the 
cysteine-rich fibroblast growth factor receptor family (40), were 
increased in the pituitaries of mir-7a2 KO mice (Figure 5E). To 
test whether predicted mir-7 targets were repressed by increased 
miR-7 levels, we overexpressed miR-7a2 using a recombinant ade-
novirus (Ad–miR-7a2) in 2 gonadotroph cell lines, aT3 and LbT2, 
and observed significant repression of several predicted miR-7 tar-
get candidates (Supplemental Figure 4, C and D). Together, these 
results reveal a tissue-specific regulation of direct and secondary 
miR-7 targets in the pituitary, with strong effects on upstream regu-
lators of prostaglandin and BMP4 signaling.
miR-7 targets Ptgfrn and Glg1 regulate expression and secretion 
of pituitary gonadotropins. To investigate the role of the identified 
miR-7 target genes in pituitary function, we undertook an unbi-
ased approach and silenced the 55 most regulated miR-7 targets 
using smart-pool siRNAs in the aT3 and LbT2 pituitary cell lines 
and analyzed the effect on expression levels of Fshb and Cga. We 
found that silencing of both Ptgfrn and Glg1 induced hormone 
transcription, indicating that these genes may act as negative reg-
ulators of pituitary hormone transcription (Supplemental Figure 
5, A and B). The 3′ UTRs of Ptgfrn and Glg1 contain 1 or 2 7mer 
miRNA-recognition sequences for miR-7, respectively, suggesting 
they are direct targets of miR-7. To confirm this, we cloned the 
WT or mutated 3′ UTRs of Ptgfrn and Glg1 into luciferase reporter 
constructs, performed luciferase assays, and demonstrated that 
both Ptgfrn and Glg1 were direct target genes of miR-7a (Figure 6, 
A and B). Next, we validated the findings from the siRNA screen in 
a separate experiment and detected a more than 1.5-fold upregula-
tion of Fshb when Ptgfrn or Glg1 was silenced by RNA interference 
(Figure 6, C and D). In addition, knockdown of Ptgfrn increased 
Lhb expression by 1.4-fold in LbT2 cells, while Cga was modestly 
regulated (Figure 6C). In contrast, overexpression of Ptgfrn or Glg1 
downregulated expression of Fshb, Lhb, and Cga (Figure 6E).
PTGFRN is known to antagonize the physiological action of 
prostaglandin F2 α (PGF2α), pharmaceutically also termed dino-
prost, on its cognate receptor, PTGFR (38, 39). Activation of PTG-
FR by dinoprost is coupled to stimulatory Gq/G11-type G proteins, 
which leads to an increase in intracellular calcium levels (41). To 
investigate a potential mechanistic role of PGF2α signaling in gonad-
otroph cells, we tested whether activation of PTGFR would induce 
the expression of pituitary hormones in LbT2 cells following treat-
ment with 10 nM dinoprost. Indeed, administration of dinoprost 
resulted in increased expression levels of both gonadotropin genes, 
Fshb and Lhb, after 4 and 8 hours (Supplemental Figure 6, A and B). 
We then tested whether reduced activity of PTGFRN, the negative 
regulator of PTGFR, would further enhance the observed pharma-
cological effects of PGF2α on pituitary hormone expression. To this 
end, we silenced Ptgfrn in gonadotroph cells and treated them with 
dinoprost for 8 hours. We found that loss of Ptgfrn further amplified 
the dinoprost-dependent induction of Fshb and Lhb (Figure 6, F and 
G), underscoring the specificity of a PGF2α/PTGFRN/PTGFR axis 
to regulate hormone expression. In addition, silencing of Ptgfrn 
resulted in increased secretion of LH in LbT2 cells (Figure 6H).
In addition to the negative regulation of gonadotropin produc-
tion by PTGFRN, BMP signaling has also been shown to interfere 
with hormone production in pituitary gonadotrophs (42, 43). Given 
tamoxifen-treated UBC-Cre × mir-7a2fl/fl mice as compared with 
control mir-7a2fl/fl mice or UBC-Cre × mir-7a2fl/fl mice that received 
only vehicle (Figure 4G). Moreover, testicular expression of the 
Leydig cell marker CYP17A1 was reduced by 35% (Figure 4H). 
Together, these data demonstrate that acute ablation of mir-7a2 in 
adult mice is sufficient to recapitulate hypopituitarism and hypo-
gonadism observed in constitutive mir-7a2 KO mice.
Dysregulated pituitary gene expression and miR-7a target dere-
pression in mir-7a2 ablated mice. To gain insights into the molecu-
lar mechanisms of miR-7a2–dependent pituitary dysfunction, we 
performed RNA-Seq of mir-7a2 KO and WT littermate mice and 
analyzed the expression of genes known to be involved in pituitary 
development, gonadotrope function, and/or in LH or FSH subunit 
gene expression. Established key factors of early pituitary function 
(Egr1, Gnrhr, Acvr1, Acvr1b, Acvr1c, Acvr2a, Acvr2b, Smad1, Smad2, 
Smad4 –7, Smad9, and Foxl2) (Supplemental Figure 4A) and devel-
opment (Gli2, Gli3, Nr5a1, Pitx1, Pitx2, Isl1, Tbx19, Pou1f1, Prop1, 
Hes1) remained unchanged between constitutive mir-7a2 KO and 
control mice, while Grem1, coding for gremlin 1, a secreted BMP4 
antagonist (37), the zinc finger protein Gli1, and the LIM homeo-
box protein 4 (Lhx4) were strongly reduced in mir-7a2 KO mice 
(Figure 5A). In tamoxifen-induced UBC-Cre × mir-7a2fl/fl mice, we 
confirmed that mRNA levels of Grem1, Gli1, and Lhx4 were similar-
ly reduced, suggesting that these genes may be relevant for miR-
7a2–dependent effects in the pituitary (Figure 5B). Direct target 
genes of miRNAs were expected to be upregulated in miRNA loss-
of-function models. To identify potential direct targets of miR-7, 
we performed bioinformatic analysis and found that mRNAs car-
rying a miR-7 response element were preferentially upregulated in 
mir-7a2 KO mice (Figure 5C). No seed enrichment was observed 
for predicted targets of ubiquitously expressed mir-16, which is 
also abundant in the pituitary (Figure 5C). Interestingly, we did 
not measure a significant upregulation (except Pfn2 and Prkcb) 
of the strongest miR-7 targets previously described in pancreatic 
islets to regulate insulin secretion (22) (Supplemental Figure 4B), 
indicating a tissue-specific regulation of miR-7 target genes. Using 
a cut-off of 1.3-fold upregulation, RNA-Seq revealed 55 potential 
direct target transcripts of miR-7. We analyzed expression of these 
genes in tamoxifen-induced UBC-Cre × mir-7a2fl/fl mice and con-
firmed derepression of several predicted miR-7 targets (Figure 5D). 
Notably, Ptgfrn, the negative regulator of prostaglandin receptor 
F2a (38, 39), was as strongly upregulated as the established miR-
7 target Cplx2 (Ptgfrn, 1.41-fold; Cplx2, 1.32-fold) (Figure 5D). We 
Figure 7. Model illustrating the molecular pathways by which miR-7a 
regulates gonadotropic hormone secretion in the pituitary.
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termed anosmia, due to defective migration of GnRH neurons 
from the olfactory placode into the hypothalamus during devel-
opment and the subsequent lack of GnRH release to the pituitary, 
leading to hypopituitarism (47). Our results show that the hypogo-
nadotropic hypogonadism in mir-7a2 KO mice is highly unlikely 
to be causally linked to miR-7 function in hypothalamic neurons 
because (a) absolute quantification of miR-7 levels demonstrates 
that miR-7a expression is 10-fold lower in hypothalamus as com-
pared with pituitary and therefore, based on miR-7b levels, in a 
range where no phenotype and target gene regulation is expected; 
(b) hypothalamic GnRH expression levels are indistinguishable 
between mir-7a2 KO and control littermates; (c) mir-7a2 KO mice 
show unaltered olfaction and normal expression of hypothalamic 
genes that are known to be involved in hypothalamus-dependent 
hypopituitarism; and (d) expression of the GnRH receptor in the 
pituitary, which is downregulated in animal models of GnRH defi-
ciency, is expressed at similar levels in mir-7a2 KO and WT control 
mice (48). In addition, miR-7 is not among the 53 miRNAs that are 
enriched in GnRH neurons compared with the surrounding non-
GnRH cells (19), further suggesting that miR-7 is unlikely to have a 
specific function in these neurons.
We have previously shown that loss of miR-7a2 in pancreatic 
β cells leads to increased β cell function and enhanced glucose- 
stimulated insulin secretion (22). Interestingly, ablation of mir-7a2 
in the pituitary leads to impaired gonadotroph cell function and 
hormone secretion. These opposing phenotypes, elicited by a loss 
of the same miRNA in 2 different neuroendocrine cell types, sug-
gest that miR-7a regulates different networks in a tissue-specific 
and context-dependent manner. The molecular mechanism for 
this observation is currently elusive, but will likely be due to dif-
ferent miRNA and target abundances and synergistic regulation of 
target genes by differentially expressed miRNAs as well as diverse 
occupancy of transcripts by RNA-binding proteins, which may 
influence binding of miRNAs to their target transcripts, thereby 
regulating the susceptibility of miRNA regulation.
The miR-7 family has previously been implicated in organ dif-
ferentiation and development (22). Our results showing already 
reduced gonad sizes and dysregulated expression of FSH and LH 
as well as direct and indirect miR-7 targets in prepubertal mice 
indicate that a developmental defect contributes to the hypogo-
nadotrohic phenotype observed in mice with constitutive genetic 
ablation of mir-7a2. However, our data obtained from temporally 
induced mir-7a2 ablation in postdevelopmental adult mice provide 
genetic evidence that impaired gonadotroph cell functions cannot 
solely be ascribed to a developmental defect and demonstrate a 
direct role of miR-7a in the maintenance of pituitary gonadotroph 
function in adult animals. Mechanistically, we identify the nega-
tive regulator of PGF2α receptor, Ptgfrn, and Glg1 as relevant direct 
target genes of miR-7a that negatively regulate gonadotropin pro-
duction and secretion. While only these targets could be linked to 
gonadotropin regulation in our pituitary cell models, we cannot 
rule out that other miR-7 targets also contribute to the defect in 
gonadotroph development and function of mir-7a2 KO mice. The 
physiological effects of prostaglandins on pituitary gonadotrophs 
have not been fully elucidated and have been in part discussed con-
troversially. While it is accepted that prostaglandins, particularly 
PGE1, act on the anterior pituitary and can induce the formation of 
that the BMP4 antagonist Grem1 was strongly reduced in miR-7a2 
KO mice, we first tested to determine whether Grem1 overexpres-
sion would increase gonadotroph expression and detected a mod-
est, but significant, increase in Fshb, Lhb, and Cga mRNA levels 
(Supplemental Figure 6C). In addition, we treated cells exogenous-
ly with recombinant GREM1 and analyzed its effect on hormone 
production. Interestingly, we detected an induction of hormone 
transcription that was comparable to that of dinoprost (Figure 6I). 
Most strikingly, when dinoprost and GREM1 were coadministered, 
we measured an additional upregulation of hormone expression 
(Figure 6I). Mechanistically, GREM1 inhibited BMP4-induced 
phosphorylation of SMAD1 in LbT2 cells when these cells were 
pretreated with recombinant GREM1 (Figure 6J). Moreover, we 
observed that GREM1 was upregulated in cells depleted in GLG1, 
while being decreased in cells overexpressing GLG1, indicating that 
the direct target GLG1 was necessary for repression of GREM1 lev-
els (Supplemental Figure 6, D and E). Together, these data identify 
Ptgfrn and Glg1 as direct targets of miR-7 that negatively regulate 
pituitary hormone transcription and secretion through regulation 
of both prostaglandin- and BMP-dependent signaling pathways.
Discussion
The results presented in this study highlight the role of miR-7a2 in 
the regulation of pituitary function and the development of hypo-
gonadotropic hypogonadism and infertility. Our data demonstrate 
that miR-7a2 is the predominant member of the miR-7 family in 
the pituitary and that constitutive genetic ablation of mir-7a2, but 
not mir-7a1, is sufficient to induce hypopituitarism and infertility. 
Deletion of mir-7a2 leads to decreased expression and profoundly 
reduced plasma levels of the pituitary gonadotropins FSH and LH, 
resulting in hypogonadism in both male and female mir-7a2 KO 
mice, as indicated by decreased steroidogenic gene expression and 
reduced sex steroid levels and gonadal sizes. We also measured 
decreased expression levels of prolactin expression in constitu-
tive and inducible mir-7a2 KO mice. This finding warrants further 
investigation and suggests that miR-7a2 either is also essential for 
lactotroph cell function in the pituitary or represses the function of 
dopaminergic neurons in the arcuate nucleus of the hypothalamus 
that are known to inhibit prolactin secretion (44). Interestingly, 
aged male and female mir-7a2 KO mice have increased fat mass, a 
phenotype that may be caused by a long-lasting and physiological-
ly relevant depletion of gonadal steroid hormones (45). However, 
we cannot exclude that miR-7a2 also influences body weight and 
energy expenditure in a partially sex steroid–independent man-
ner, for example, through neurons in the hypothalamus, where 
miR-7a2 expression has also been reported (46). The observed 
hypogonadism stems from a dysfunction of upstream components 
of the HPG axis, since ovarian function and ovulation are func-
tionally rescued when pituitary hormones are replaced in miR-7a2 
KO mice in a superovulation test. This phenotype is reminiscent 
of the disease pathology of human hypogonadotropic hypogonad-
ism, prompting the question of whether some cases of congential 
IHH of pituitary origin with as-yet-unknown genetic causes may 
be attributed to abnormal miR-7a2 levels. Further investigations 
are warranted to explore this possibility.
Cases of Kallmann’s syndrome, a form of human hypogonad-
otropic hypogonadism, are often accompanied by a loss of smell, 
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targeting vector was electroporated in C5BL/6N embryonic stem cells. 
Upon selection with G418 (Invitrogen), clones were picked, expanded, 
and verified for integration by Southern blotting. Positive clones were 
microinjected in BALB/c blastocytes and subsequently transferred 
into pseudopregnant females to generate chimeric offspring. Chime-
ras were then bred with C57BL/6 females to produce heterozygotes, 
which were crossed with Flipase mice to delete the neor cassette. Mice 
were bred with B6.C-Tg(CMV-cre)1Cgn/j mice (Jackson Laboratory) 
for deleting mir-7b. Genotyping of mir-7b KO mice was performed by 
PCR using primers listed in Supplemental Table 2.
DEXA. DEXA measurements of fat and lean body mass were per-
formed as whole animal scans using an animal CT-Scanner (LaTheta) 
at 1-mm intervals from the head to the base of the tail. Images were 
analyzed using the LaTheta software.
Immunostainings. Mice were perfused with 4% paraformaldehyde, 
and organs were postfixed overnight at 4°C and embedded in paraffin. 
Microtome sections were subjected to antigen retrieval in a pressure 
oven in 10 mM sodium citrate, pH 6.0, for 10 minutes at 95°C. Sec-
tions were permeabilized and blocked in PBS containing 0.1% Triton 
X-100, 1% BSA, and 5% goat serum. Primary antibody binding was 
performed overnight at 4°C, while secondary antibody incubation was 
carried out at room temperature for 1 hour.
For morphometric analysis of pituitaries, 5-μm sections were 
cut and 5 sections from each pituitary were stained with anti-LH or 
anti-FSH antibodies and Hoechst dye to stain nuclei. Sections were 
scanned using a 20× objective of a Zeiss Apotome microscope. The 
number of FSH- or LH-positive cells compared with total cell num-
ber was determined using CellProfiler software. For morphometrical 
quantification of testicular Leydig cells, 4-μm paraffin sections were 
cut and 5 sections per testis were stained with anti-CYP17A1 anti-
body and Hoechst dye to stain nuclei. Sections were scanned using a 
20× objective of the Panoramic 250 Slide Scanner (3D Histech). The 
area fractions of CYP17A1-positive cells relative to total cell area were 
determined using ImageJ (Fiji, NIH) software.
Western blots. Cells were lysed in RIPA buffer containing protease 
inhibitors (Roche) and HALT phosphatase inhibitors (Pierce). Protein 
concentrations were measured by the Bradford method. Proteins were 
separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and blocked in 5% milk/TBS-T or 5% BSA/TBS-T for 1 hour. Mem-
branes were incubated with appropriate antibodies overnight at 4°C. 
Membranes were exposed to secondary antibodies for 1 hour at room 
temperature and developed using ECL Western Blotting Substrate.
Illumina RNA-Seq and analysis. Library preparation was as follows: 
the quality of the isolated RNA was determined with a Qubit (1.0) 
Fluorometer (Life Technologies) and a Bioanalyzer 2100 (Agilent). 
Only those samples with a 260/280 nm ratio between 1.8 and 2.1 and 
a 28S/18S ratio within 1.5 and 2.0 were further processed. The TruSeq 
RNA Sample Prep Kit v2 (Illumina) was used in the succeeding steps. 
Briefly, total RNA samples (100–1000 ng) were poly-A enriched and 
then reverse transcribed into double-strand cDNA. The cDNA sam-
ples were fragmented, endrepaired, and polyadenylated before liga-
tion of TruSeq adapters containing the index sequence for multiplex 
sequencing. Multiplexing fragments containing TruSeq adapters on 
both ends were selectively enriched with PCR. The quality and quan-
tity of the enriched libraries were validated using Qubit (1.0) Fluorom-
eter and the Caliper GX LabChip GX (Caliper Life Sciences Inc.). The 
product is a smear with an average fragment size of approximately 
cyclic AMP, a direct effect on LH and FSH could not be established 
(49). In the case of PGF2α, known as dinoprost, however, existing 
data suggest that PGF2α treatment may regulate LH stores and 
release (50–52). Our data now demonstrate that in pituitary gonad-
otroph cell lines, PGF2α/dinoprost increases gonadotropin produc-
tion and that the direct miR-7a target PTGFRN acts as a negative 
modulator in a PGF2α/PTGFRN/PTGFR regulatory circuit.
In addition, we here describe the inhibitory role of the miR-7a 
target GLG1 in gonadotroph cell functions. While the precise phys-
iological functions of GLG1 in pituitary hormone homeostasis are 
unknown, our data suggest that GLG1 negatively affects expres-
sion of the BMP antagonist GREM1. BMP4 plays a crucial role in 
the formation of the anterior pituitary by regulating diverse cel-
lular responses, such as cell differentiation, migration, adhesion, 
and proliferation (53), but also has been described as inhibiting 
FSH production (42, 54). BMPs activate BMP receptors, which in 
turn recruit and phosphorylate SMAD proteins that translocate to 
the nucleus to repress Fshb subunit gene expression. Furthermore, 
BMPs can antagonize the activin-mediated effects known for stim-
ulating FSH release (42). We propose that in miR-7a2 KO mice, the 
drastic reduction in GREM1 levels is partly mediated by dysinhi-
bition of its negative regulator and miR-7 target GLG1, leading to 
derepression of BMP4 and, consequently, increased BMP activity, 
which affects pituitary development defect and impairs gonad-
otroph function in adult mice (Figure 7). Indeed, in this context, 
we demonstrate that GREM1 acts as a BMP4 antagonist to reduce 
phosphorylation of SMAD proteins in pituitary LbT2 cells.
In summary, our data reveal miR-7a2 as a crucial regulator of 
pituitary gonadotroph cell function and describe how the loss of 
mir-7a2 leads to hypogonadotropic hypogonadism. Mutations in 
the miR-7a2 gene and within the binding sites in the 3′ UTRs of 
its most regulated targets should be considered as potential genet-
ic causes for hypogonadotropic hypogonadism in humans. Our 
findings also characterize PTGFRN and GLG1 as two novel target 
genes of miR-7 that negatively regulate gonadotropin production. 
Pharmacological stimulation of miR-7 activity and/or direct inhi-
bition of its targets PTGFRN and GLG1 may provide a basis to 
develop strategies to improve pituitary function in human disease.
Methods
Animal husbandry and mouse strains. All mice were on a pure C57BL/6N 
background. Mice were housed in a pathogen-free animal facility at 
the Institute of Molecular Health Sciences at ETH Zurich. The animals 
were maintained in a temperature- and humidity-controlled room on 
a 12-hour light/12-hour dark cycle (lights on from 6 am to 6 pm). Mice 
were fed a standard laboratory chow diet. Generation of mir-7a1 KO 
and mir-7a2 KO mice was described previously (22). UBC-Cre mice 
(Tg[UBC-cre/ERT2]1Ejb) were purchased from Jackson Laboratories.
Generation of mir-7b KO mice. A 15.7-kb fragment encompassing 
mmu-mir-7b was recombined into a minimal vector using homology 
arms-containing primers according to the protocol provided by Gene-
Bridges (http://www.genebridges.com; primers listed in Supplemental 
Table 2). The mir-7b gene was juxtaposed with a loxP-containing neor 
cassette 97 bp upstream of the miRNA precursor sequence. Following 
expression of the Cre in bacteria, the neor cassette was removed and 
a second Frt/loxP/neor cassette was introduced 498 bp downstream 
of the miR-7b gene (Supplemental Figure 1A). Upon linearization, the 
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mental cage. Mice were reintroduced into the experimental cage, and 
the elapsed time was recorded once they uncovered the chow pellet.
Recombinant adenovirus. Mouse miR-7a2–expressing vectors were 
generated by PCR amplification of a 250-bp fragment spanning the 
pre-miR-7a2 genomic sequences. Fragments were cloned at XhoI sites 
of pAD5 for adenovirus production (Viraquest). The miR-7a adenovi-
ruses expressed GFP from an independent promoter, and the control 
adenovirus (Ad-GFP) was identical except that it lacked the miRNA. 
Expression was confirmed by TaqMan qPCR.
Chemical compounds. BMP4, dinoprost, and GnRH were pur-
chased from Sigma-Aldrich. Grem1 was obtained from R&D Systems.
Cell lines. Pituitary cell lines α T3 and L β T2 were provided by P. 
Mellon (UCD, Davis, California, USA) (58, 59).
Antibodies. Antibodies recognizing mouse FSHb and LHb were 
obtained from A. Parlow (National Hormone and Peptide Program, 
Harbor-UCLA Medical Center, Torrance, California, USA). TUBB3 
(catalog 4466), β-actin (catalog 4970), SMAD1 (catalog 6944), and 
phospho-SMAD1/5/9 (catalog 13820) were purchased from Cell Sig-
naling Technology. CYP17A1 antibody was purchased from Santa Cruz 
Biotechnology Inc. (catalog sc-46081).
Primer sequences. See Supplemental Table 3.
Statistics. For all experiments, data are shown as mean ± SD if 
not stated otherwise. To determine statistical significance between 2 
groups, 2-tailed Student’s t test was used. For multiple comparisons, 
1-way ANOVA followed by Tukey’s post-test was used. A P value of 
less than 0.05 was considered statistically significant. Statistical anal-
ysis was performed using GraphPad Prism 4 (GraphPad software).
Study approval. All animal experiments were approved by the Kan-
tonale Veterinäramt Zürich, Zurich, Switzerland.
Accession codes. All raw RNA-Seq data were deposited in the Euro-
pean Nucleotide Archive (ENA PRJEB12612; http://www.ebi.ac.uk/ena).
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260 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH 
8.5, with 0.1% Tween 20.
Cluster generation and sequencing. The TruSeq PE Cluster Kit 
v3-cBot-HS or TruSeq SR Cluster Kit v3-cBot-HS (Illumina Inc.) was 
used for cluster generation using 10 pM of pooled normalized libraries 
on the cBOT. Sequencing was performed on the Illumina HiSeq 2000 
paired end at 2 × 101 bp or single-end 100 bp using the TruSeq SBS Kit 
v3-HS (Illumina Inc.).
Data analysis. RNA-Seq reads were quality checked with FastQC 
(Babraham Bioinformatics), which computes various quality metrics for 
raw reads. Reads were aligned to the genome and transcriptome with 
TopHat v 1.3.3 (https://ccb.jhu.edu/software/tophat/manual.shtml). 
Before mapping, the low-quality ends of the reads were clipped (3 bas-
es from the read start and 10 bases from the read end). TopHat was 
run with default options. The fragment length parameter was set to 
100 bases, with an SD of 100 bases. Based on these alignments, the 
distribution of the reads across genomic features was assessed. Iso-
form expression was quantified with the RSEM algorithm (http://www.
biomedcentral.com/1471-2105/12/323; BMC Bioinformatics) with the 
option for estimation of the read start position distribution turned on. 
For seed enrichment analysis, only genes with FPKM above 1.0 were 
considered. For cumulative distribution function calculations, log2 
fold-change values were corrected for 3′ UTR length biases (55).
RNA isolation and real-time pPCR. RNA was isolated using 
TRIzol reagent (Invitrogen) according to the manufacturer’s proto-
col. RNA was subjected to DNaseI treatment with the DNA-free kit 
(Ambion) when necessary. RNA was reverse transcribed using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosyste-
ms). qPCR was performed with a LC480 II Lightcycler (Roche) and 
SYBR Fast Universal Mastermix (Kapa). Results were normalized to 
36B4 mRNA levels. miRNA levels were measured using the TaqMan 
microRNA Assay Kit (Applied Biosystems), and the results were nor-
malized to sno-202 levels. For absolute quantification, synthesized 
mature miRNAs were used (Sigma-Aldrich).
Luciferase assays. LbT2 or aT3 cells were cultured in 24-well plates 
and transfected with 100 ng of pmirGLO reporters. Cells were assayed 
48 hours after transfection using the Dual-Luciferase Reporter Assay 
System (Promega). Results were normalized to the Renilla luciferase 
control contained in pmirGLO and expressed relative to the average 
value of the controls.
GnRH stimulation test. Female nullipara mice were given an intra-
peritoneal injection of Buserelin (GnRH agonist, Sigma-Aldrich; 0.01 
μg/μl) in 200 μl of vehicle (PBS) or vehicle alone and blood was col-
lected after 15 minutes for FSH and LH measurements.
Hormone measurements. Testosterone and estradiol were quan-
tified using the ELISA Kit from Alpco following the manufacturer’s 
instructions. For intratesticular testosterone analysis, lipid extraction 
was performed using 2× diethylether. Serum LH and FSH concentra-
tions were measured using immunofluorometric assays as described 
previously (55). For measuring intratesticular and serum testosterone, 
both sera and tissue homogenates were extracted twice with 2 ml of 
diethyl ether, followed by conventional RIA (56).
Olfaction behavioral test. A buried food test was conducted as pre-
viously described (57). Nine-week-old mice were fasted for 24 hours 
and then were allowed to acclimate in the experimental cage for 5 min-
utes prior to the test. Mice were transferred to an empty cage, while a 
1.5 g pellet of chow was buried 1 cm below the bedding in the experi-
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